Definitions for coronavirus disease 2019 reinfection, relapse and PCR re-positivity.
作者信息
Yahav Dafna, Yelin Dana, Eckerle Isabella, Eberhardt Christiane S, Wang Jianwei, Cao Bin, Kaiser Laurent
机构信息
Infectious Diseases Unit, Rabin Medical Centre, Beilinson Hospital, Petah-Tikva, Israel; Sackler Faculty of Medicine, Tel Aviv University, Ramat Aviv, Israel.
Infectious Diseases Unit, Rabin Medical Centre, Beilinson Hospital, Petah-Tikva, Israel; Sackler Faculty of Medicine, Tel Aviv University, Ramat Aviv, Israel.
出版信息
Clin Microbiol Infect. 2021 Mar;27(3):315-318. doi: 10.1016/j.cmi.2020.11.028. Epub 2020 Dec 5.
Abstract
摘要
相似文献
1
Definitions for coronavirus disease 2019 reinfection, relapse and PCR re-positivity.
Clin Microbiol Infect. 2021 Mar;27(3):315-318. doi: 10.1016/j.cmi.2020.11.028. Epub 2020 Dec 5.
2
Viral Shedding among Re-Positive Severe Acute Respiratory Syndrome Coronavirus-2 Positive Individuals in Republic of Korea.
Viruses. 2021 Oct 17;13(10):2089. doi: 10.3390/v13102089.
3
Immune response variables and viral mutations impact on COVID-19 reinfection and relapse.
Int Immunopharmacol. 2021 Nov;100:108108. doi: 10.1016/j.intimp.2021.108108. Epub 2021 Sep 8.
4
Audio Interview: A Look at Covid-19 Prevention and Care in 2020.
N Engl J Med. 2020 Dec 31;383(27):e147. doi: 10.1056/NEJMe2036225.
5
Antibody Response and Variant Cross-Neutralization After SARS-CoV-2 Breakthrough Infection.
JAMA. 2022 Jan 11;327(2):179-181. doi: 10.1001/jama.2021.22898.
6
SARS-CoV-2 reinfection and implications for vaccine development.
Hum Vaccin Immunother. 2020 Dec 1;16(12):3061-3073. doi: 10.1080/21645515.2020.1830683.
7
Dynamics of viral load and anti-SARS-CoV-2 antibodies in patients with positive RT-PCR results after recovery from COVID-19.
Korean J Intern Med. 2021 Jan;36(1):11-14. doi: 10.3904/kjim.2020.325. Epub 2020 Nov 25.
8
The kinetics of viral load and antibodies to SARS-CoV-2.
Clin Microbiol Infect. 2020 Dec;26(12):1690.e1-1690.e4. doi: 10.1016/j.cmi.2020.08.043. Epub 2020 Sep 6.
9
Neutralizing Antibodies Against SARS-CoV-2 Variants After Infection and Vaccination.
JAMA. 2021 May 11;325(18):1896-1898. doi: 10.1001/jama.2021.4388.
10
SARS-CoV-2 show no infectivity at later stages in a prolonged COVID-19 patient despite positivity in RNA testing.
J Med Virol. 2021 Jul;93(7):4570-4575. doi: 10.1002/jmv.27001. Epub 2021 Apr 23.
引用本文的文献
1
Exploring the oncogenic potential of SARS-CoV-2 in the gastrointestinal tract.
World J Gastroenterol. 2025 Aug 21;31(31):105665. doi: 10.3748/wjg.v31.i31.105665.
2
Risk of SARS-CoV-2 Reinfections Among Healthcare Workers of Four Large University Hospitals in Northern Italy: Results of an Online Survey Within the ORCHESTRA Project.
Vaccines (Basel). 2025 Jul 31;13(8):815. doi: 10.3390/vaccines13080815.
3
Clinical and immunological insights into SARS-CoV-2 reinfection: a propensity score-matched cohort study.
BMC Infect Dis. 2025 Aug 1;25(1):970. doi: 10.1186/s12879-025-11398-0.
4
Critical illness in immunocompromised patients: insights into relapse or persistent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): case series report.
J Med Case Rep. 2025 Jul 27;19(1):371. doi: 10.1186/s13256-025-05431-8.
5
Secondary Organising Pneumonia Among Immunocompromised Multiple Sclerosis Patients Treated With Ocrelizumab Following COVID-19 Infection: Two Case Reports With Literature Review.
Respirol Case Rep. 2025 Jul 9;13(7):e70268. doi: 10.1002/rcr2.70268. eCollection 2025 Jul.
6
Impact of SARS-CoV-2 infection on bispecific antibody treatment in patients with B-cell lymphoproliferative disorders.
Blood Adv. 2025 Aug 26;9(16):4180-4189. doi: 10.1182/bloodadvances.2024015406.
7
An online survey among convalescents 5 months post SARS-CoV-2 infection in China.
Biosaf Health. 2024 Jun 13;6(4):206-215. doi: 10.1016/j.bsheal.2024.06.001. eCollection 2024 Aug.
8
Difference of clinical characteristics in patients with reinfection and primary infection variants of SARS-CoV-2: a retrospective study in China.
BMC Infect Dis. 2025 Feb 5;25(1):173. doi: 10.1186/s12879-025-10509-1.
9
Long-term effectiveness of an ultra-rapid rollout vaccination campaign with BNT162b2 on the incidence of SARS-CoV-2 infection.
iScience. 2024 Oct 10;27(11):111117. doi: 10.1016/j.isci.2024.111117. eCollection 2024 Nov 15.
10
End-to-end SARS-CoV-2 transmission risks in sport: Current evidence and practical recommendations.
S Afr J Sports Med. 2021 Jan 15;33(1):v33i1a11210. doi: 10.17159/2078-516X/2021/v33i1a11210. eCollection 2021.
本文引用的文献
1
Reinfection with SARS-CoV-2 and Waning Humoral Immunity: A Case Report.
Vaccines (Basel). 2022 Dec 20;11(1):5. doi: 10.3390/vaccines11010005.
2
Genomic evidence for reinfection with SARS-CoV-2: a case study.
Lancet Infect Dis. 2021 Jan;21(1):52-58. doi: 10.1016/S1473-3099(20)30764-7. Epub 2020 Oct 12.
3
What reinfections mean for COVID-19.
Lancet Infect Dis. 2021 Jan;21(1):3-5. doi: 10.1016/S1473-3099(20)30783-0. Epub 2020 Oct 12.
4
A Case of Early Reinfection With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Clin Infect Dis. 2021 Nov 2;73(9):e2827-e2828. doi: 10.1093/cid/ciaa1436.
5
A systematic review of antibody mediated immunity to coronaviruses: kinetics, correlates of protection, and association with severity.
Nat Commun. 2020 Sep 17;11(1):4704. doi: 10.1038/s41467-020-18450-4.
6
Seasonal coronavirus protective immunity is short-lasting.
Nat Med. 2020 Nov;26(11):1691-1693. doi: 10.1038/s41591-020-1083-1. Epub 2020 Sep 14.
7
The Power of Antibody-Based Surveillance.
N Engl J Med. 2020 Oct 29;383(18):1782-1784. doi: 10.1056/NEJMe2028079. Epub 2020 Sep 1.
8
Clinical, immunological and virological characterization of COVID-19 patients that test re-positive for SARS-CoV-2 by RT-PCR.
EBioMedicine. 2020 Sep;59:102960. doi: 10.1016/j.ebiom.2020.102960. Epub 2020 Aug 24.
9
Coronavirus Disease 2019 (COVID-19) Re-infection by a Phylogenetically Distinct Severe Acute Respiratory Syndrome Coronavirus 2 Strain Confirmed by Whole Genome Sequencing.
Clin Infect Dis. 2021 Nov 2;73(9):e2946-e2951. doi: 10.1093/cid/ciaa1275.
10
Duration of infectiousness and correlation with RT-PCR cycle threshold values in cases of COVID-19, England, January to May 2020.
Euro Surveill. 2020 Aug;25(32). doi: 10.2807/1560-7917.ES.2020.25.32.2001483.
Zotero 插件